Zanubrutinib and acalabrutinib for CLL: potential alternatives to ibrutinib? 

Susan O’Brien, MD, of the University of California, Irvine, CA, talks about up and coming therapies for chronic lymphocytic leukemia (CLL), and mentions the point that while ibrutinib has shown high response rates, efficacy data for both acalabrutinib and zanubrutinib in clinical trials has looked promising. This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.